Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

590 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Minor GPI(-) granulocyte populations in aplastic anemia and healthy individuals derived from a few PIGA-mutated hematopoietic stem progenitor cells.
Mizumaki H, Tran DC, Hosokawa K, Hosomichi K, Zaimoku Y, Takamatsu H, Yamazaki H, Ishiyama K, Yamazaki R, Fujiwara H, Tajima A, Nakao S. Mizumaki H, et al. Among authors: takamatsu h. Blood Cancer J. 2023 Nov 8;13(1):165. doi: 10.1038/s41408-023-00932-5. Blood Cancer J. 2023. PMID: 37938545 Free PMC article. No abstract available.
Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone.
Yoroidaka T, Yamashita T, Murata R, Yoshihara K, Yoshihara S, Ueda M, Nakao S, Matsue K, Takamatsu H. Yoroidaka T, et al. Among authors: takamatsu h. Anticancer Res. 2023 Jan;43(1):157-165. doi: 10.21873/anticanres.16145. Anticancer Res. 2023. PMID: 36585165
3D CNN-based Deep Learning Model-based Explanatory Prognostication in Patients  with Multiple Myeloma using Whole-body MRI.
Morita K, Karashima S, Terao T, Yoshida K, Yamashita T, Yoroidaka T, Tanabe M, Imi T, Zaimoku Y, Yoshida A, Maruyama H, Iwaki N, Aoki G, Kotani T, Murata R, Miyamoto T, Machida Y, Matsue K, Nambo H, Takamatsu H. Morita K, et al. Among authors: takamatsu h. J Med Syst. 2024 Mar 8;48(1):30. doi: 10.1007/s10916-024-02040-8. J Med Syst. 2024. PMID: 38456950
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan.
Horigome Y, Iino M, Harazaki Y, Kobayashi T, Handa H, Hiramatsu Y, Kuroi T, Tanimoto K, Matsue K, Abe M, Ishida T, Ito S, Iwasaki H, Kuroda J, Shibayama H, Sunami K, Takamatsu H, Tamura H, Hayashi T, Akagi K, Maeda T, Yoshida T, Mori I, Shinozaki T, Iida S. Horigome Y, et al. Among authors: takamatsu h. Ann Hematol. 2024 Feb;103(2):475-488. doi: 10.1007/s00277-023-05428-7. Epub 2023 Sep 11. Ann Hematol. 2024. PMID: 37695378 Free PMC article.
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
Sunami K, Fuchida SI, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Imada K, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Onishi R, Tada K, Iida S. Sunami K, et al. Among authors: takamatsu h. Hematol Oncol. 2023 Aug;41(3):442-452. doi: 10.1002/hon.3105. Epub 2022 Dec 15. Hematol Oncol. 2023. PMID: 36433829 Clinical Trial.
Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs.
Takamatsu H, Matsuda T, Mizuno S, Takahashi T, Fuchida SI, Hanamura I, Kataoka K, Tsukada N, Matsumoto M, Hangaishi A, Doki N, Uchida N, Sawa M, Maruyama Y, Kurahashi S, Nagafuji K, Harazaki Y, Kako S, Iida S, Ichinohe T, Kanda Y, Atsuta Y, Sunami K; Multiple Myeloma Working Group in the Japanese Society for Transplantation and Cellular Therapy. Takamatsu H, et al. Haematologica. 2023 Dec 1;108(12):3399-3408. doi: 10.3324/haematol.2023.283202. Haematologica. 2023. PMID: 37470160 Free PMC article.
590 results